ACHN’s 4-week data for ACH-1625 are not especially noteworthy one way or the other, IMO. However, the results illustrate how much harder it’s going to be to interpret HCV data now that all patients are getting tested for IL-28B status.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”